Meet The Team
CEO & Co-Founder
David has a 30+ year track record of commercial success in the pharmaceutical industry with experience across sales, marketing, market analytics, global commercial strategy, business development, R&D and international policy. He successfully developed, launched and managed medicines globally and locally, including niche medicines and $1bn+ blockbusters with access in 100+ markets. He was Global Commercial Lead for anti-infectives at GSK, spending time embedded with the R&D organisation in Collegeville, Pennsylvania and subsequently at GSK’s London HQ. As well as developing and delivering disease area, pipeline and product strategies, David led investment positions for drug development phases and in-license products, gaining significant (£10M +) investments for drug development and manufacturing facilities. David has recently run his own consultancy business that delivers commercial and R&D support to SMEs, providing pipeline and access strategies, including market assessment and opportunity analysis, developing investment positions, country/regional access plans and aligning strategies with regulatory frameworks.
CTO & Co-Founder
Dr Scott is a Senior Lecturer at University of Strathclyde in the Department of Pure and Applied Chemistry. Dr Scott has a PhD in Drug Development in which he investigated Nucleic Acid Binding Compounds utilising medicinal chemistry, microbiology, statistical analysis, computational drug design, formulation science and synthetic organic chemistry. Fraser was the project champion for the Minor Groove Binder Project at University of Strathclyde which laid the foundation for the Rostra platform of molecules. Fraser will lead on the research and development of S-MGBs.
COO & Co-Founder
Mr Mulgrew has a strong track record as project manager bringing together a unique combination of skills and experience around innovation, technology, business development and innovation management in both global and start up organisations. He has successfully delivered a wide-range of large-scale capital-intensive programmes and technology transfer in regulated manufacturing (pharmaceutical, medical device and food) industries. He was manager within corporate engineering at Intergra LifeScience and an industry project manager at the Centre for Continuous Manufacturing and Advanced Crystallisation based at Strathclyde working on collaborative R&D and tech transfer. He has extensive experience managing complex technical programmes and collaborative R&D projects, as well as building and maintaining high-performance cross-functional teams. Mr Mulgrew has knowledge and experience in licensing and spin-out creation, academic-industry R&D, leveraged and collaborative funding, business plan development, manufacturing operations and innovation management.
Prof. Suckling was Freeland Professor of Chemistry at the University of Strathclyde from 1989 to 2012. Much of Colin’s work has been strategic, including the development of inter-institutional and interdisciplinary research partnerships, notably the research collaboration with the University of Glasgow (WestCHEM), which was recognised publicly with his award of OBE in 2006. Colin has extensive experience into the commercialisation of research both through his work as a senior officer of the University and specifically in the commercialisation of discoveries related to the synthesis of leucovorin, a compound extensively used as part of cancer chemotherapy. Together with his team, he discovered and patented innovations related to the MGB Project. He will be a scientific advisor for RTx and leading on the strategic development aspects of RTx. Colin was a member of the Scottish Medicines Consortium (2012-2014).
Professor Hunter’s expertise is in molecular microbiology and microbial physiology. As Principal Research Scientist at Pfizer Global, he led a team using molecular genetics in drug discovery and strain improvement. He joined Strathclyde in 1995 as Professor of Molecular Microbiology. Translational activities include startup of CRO Bioflux (1987), SAB at formation of Biotica (1996, now Isomerase Therapeutics) and SAB at formation of AciesBio (2006). He will be a scientific advisor for RTx leading on the biological and clinical development aspects of the RTx platform.